ATE356145T1 - Polypeptide zur regenerierung des nervensystems - Google Patents

Polypeptide zur regenerierung des nervensystems

Info

Publication number
ATE356145T1
ATE356145T1 AT98939690T AT98939690T ATE356145T1 AT E356145 T1 ATE356145 T1 AT E356145T1 AT 98939690 T AT98939690 T AT 98939690T AT 98939690 T AT98939690 T AT 98939690T AT E356145 T1 ATE356145 T1 AT E356145T1
Authority
AT
Austria
Prior art keywords
polypeptides
nervous system
regenerating
useful
amino acids
Prior art date
Application number
AT98939690T
Other languages
English (en)
Inventor
Annie Meiniel
Hubert Monnerie
Stephane Gobron
Original Assignee
Neuronax
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuronax, Inst Nat Sante Rech Med filed Critical Neuronax
Application granted granted Critical
Publication of ATE356145T1 publication Critical patent/ATE356145T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98939690T 1997-07-16 1998-07-16 Polypeptide zur regenerierung des nervensystems ATE356145T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9709016A FR2766190B1 (fr) 1997-07-16 1997-07-16 Nouveaux peptides et polypeptides utiles dans la regeneration du systeme nerveux

Publications (1)

Publication Number Publication Date
ATE356145T1 true ATE356145T1 (de) 2007-03-15

Family

ID=9509272

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98939690T ATE356145T1 (de) 1997-07-16 1998-07-16 Polypeptide zur regenerierung des nervensystems

Country Status (10)

Country Link
US (1) US6995140B1 (de)
EP (1) EP1003784B1 (de)
JP (1) JP2001510034A (de)
AT (1) ATE356145T1 (de)
AU (1) AU8811298A (de)
CA (1) CA2297303C (de)
DE (1) DE69837265T2 (de)
ES (1) ES2281132T3 (de)
FR (1) FR2766190B1 (de)
WO (1) WO1999003890A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2910003B1 (fr) * 2006-12-18 2012-10-26 Neuronax Nouveaux peptides et polypeptides a stabilite amelioree utiles dans la regeneration du systeme nerveux
EP2027868A1 (de) * 2007-08-24 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von SCO-Spondin zur Hemmung oder Verhinderung von durch Zelltod-Rezeptor-Liganden vermittelter Apoptose
FR3024364B1 (fr) * 2014-07-31 2016-09-02 Neuronax Oligopeptides particuliers comme medicaments anti-angiogeniques
FR3041644B1 (fr) * 2015-09-25 2018-01-05 Neuronax Polypeptides cycliques, leur procede d'obtention et leur application en therapeutique
EP3330284A1 (de) 2016-12-05 2018-06-06 Neuronax Sa Verwendung von peptidverbindungen zur förderung des überlebens, des wachstums und der zelldifferenzierung
EP3360884A1 (de) 2017-02-10 2018-08-15 Neuronax Verbessertes verfahren zur herstellung eines dodecapeptids
EP4041279A1 (de) 2019-10-07 2022-08-17 Axoltis Pharma Systemische verabreichung von peptiden zur behandlung von rückenmarksverletzungen und / oder zur remyelinisierung
IL293426A (en) 2019-12-05 2022-07-01 Axoltis Pharma Peptide compositions and methods for treating tau-related diseases
KR20240035381A (ko) 2021-07-09 2024-03-15 아쏠티스 파마 시냅스 전달을 강화하기 위한 sco-스폰딘-유래 폴리펩타이드
EP4190347A1 (de) 2021-12-01 2023-06-07 Axoltis Pharma Von sco-spondin abgeleitete polypeptide zur behandlung der dysfunktion biologischer barrieren

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
FR2678283A1 (fr) * 1991-06-25 1992-12-31 Centre Nat Rech Scient Sequences de nucleotides, sequences d'acides amines correspondantes, et leurs applications biologiques.
WO1994006464A1 (en) * 1992-09-17 1994-03-31 New York University Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites

Also Published As

Publication number Publication date
WO1999003890A1 (fr) 1999-01-28
DE69837265T2 (de) 2007-11-15
CA2297303C (fr) 2012-02-21
US6995140B1 (en) 2006-02-07
FR2766190B1 (fr) 2001-11-02
EP1003784A1 (de) 2000-05-31
FR2766190A1 (fr) 1999-01-22
DE69837265D1 (de) 2007-04-19
EP1003784B1 (de) 2007-03-07
ES2281132T3 (es) 2007-09-16
JP2001510034A (ja) 2001-07-31
CA2297303A1 (fr) 1999-01-28
AU8811298A (en) 1999-02-10

Similar Documents

Publication Publication Date Title
DE69735375D1 (de) Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
DE69835279D1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
CA2263889A1 (en) P-selectin ligand proteins
ATE133681T1 (de) Mykobakterielle rekombinanten und peptide
DE60132075D1 (de) Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren
WO1995021919A3 (en) Protein having tpo activity
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
DE60218179D1 (de) Peptide zur behandlung von tumoren und anderen bedingungen die die entfernung oder zerstörung von zelle erfordern
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
DE69837265D1 (de) Polypeptide zur regenerierung des nervensystems
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
ATE408685T1 (de) Antimikrobielle peptide, abstammend von ubiquicidin
GB8821785D0 (en) Peptide compounds
WO1995030001A3 (en) Novel p-selectin ligand protein
ATE291088T1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
CO4480058A1 (es) Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa
DE69524415D1 (de) UNGESPLEISSTE VARIANTEN DES gp350/220
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
FR2792651A1 (fr) Sequence genomique et polypeptides de pyrococcus abyssi, leurs fragments et leurs utilisations
DE60234843D1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
DE69534738D1 (de) Leukocyten-aktivierender Faktor
PT811068E (pt) Variantes da adnase i humana

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1003784

Country of ref document: EP